Joel Picus
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
Papers in
- Oncology 50
- Pancreatic and Hepatic Oncology Research 14
- Cancer Treatment and Pharmacology 9
- Colorectal Cancer Surgical Treatments 8
- Colorectal Cancer Treatments and Studies 7
-
- Prostate Cancer Treatment and Research 22
- Renal cell carcinoma treatment 14
- Co-authors
- Susan Halabi (19 shared papers)Nicholas J. Vogelzang (16 shared papers)Eric Jay Small (14 shared papers)Walter Michael Stadler (12 shared papers)Jorge Alberto Garcia (8 shared papers)Christopher J. Sweeney (9 shared papers)Robert Dreicer (11 shared papers)Noah M. Hahn (7 shared papers)
- Journals
- Journal of Clinical Oncology (22 papers)Annals of Oncology (16 papers)Cancer (9 papers)International Journal of Radiation Oncology*Biology*Physics (8 papers)Cancer Chemotherapy and Pharmacology (7 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Joel Picus
140 papers receiving 19.9k citations
Joel Picus's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 8.1k
- Pulmonary and Respiratory Medicine 8.8k
- Cancer Research 3.8k
- Immunology 2.1k
- Hepatology 716
Countries citing papers authored by Joel Picus
This map shows the geographic impact of Joel Picus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Picus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Picus more than expected).
Fields of papers citing papers by Joel Picus
This network shows the impact of papers produced by Joel Picus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Picus. The network helps show where Joel Picus may publish in the future.
Co-authors
The 25 scholars most cited alongside Joel Picus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 144 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Hit paper breakdown → | 2010 | 2584 |
| 2 | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Hit paper breakdown → | 2015 | 2206 |
| 3 | Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 1586 |
| 4 | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial Hit paper breakdown → | 2018 | 816 |
| 5 | Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Hit paper breakdown → | 2008 | 753 |
| 6 | Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study Hit paper breakdown → | 1999 | 734 |
| 7 | Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) Hit paper breakdown → | 2010 | 728 |
| 8 | Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206 Hit paper breakdown → | 2010 | 645 |
| 9 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 598 |
| 10 | Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors Hit paper breakdown → | 2008 | 509 |
| 11 | 2009 | 446 | |
| 12 | 1990 | 429 | |
| 13 | 2004 | 417 | |
| 14 | 2005 | 385 | |
| 15 | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial Hit paper breakdown → | 2016 | 358 |
| 16 | Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2019 | 331 |
| 17 | 1991 | 320 | |
| 18 | 2003 | 310 | |
| 19 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Hit paper breakdown → | 2018 | 306 |
| 20 | 2006 | 278 |
About Joel Picus
Joel Picus is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 144 papers that have together received 20.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (22 papers), Pancreatic and Hepatic Oncology Research (14 papers), Renal cell carcinoma treatment (14 papers), Bladder and Urothelial Cancer Treatments (14 papers), Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Surgical Treatments (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). The work is most often cited by research in Oncology (8.1k citations), Pulmonary and Respiratory Medicine (8.8k citations), Cancer Research (3.8k citations), Immunology (2.1k citations) and Hepatology (716 citations). Joel Picus has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Susan Halabi, Nicholas J. Vogelzang, Eric Jay Small, Walter Michael Stadler, Jorge Alberto Garcia, Christopher J. Sweeney, Robert Dreicer, Noah M. Hahn, Neal J. Meropol and Robert S. DiPaola. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.